Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus

British Journal of Dermatology

Volumn 141, Issue 6, 1999, Pages 1040-1045

  Stefanidou, M P ^a   Ioannidou, D J ^a   Panayiotides, J G ^a   Tosca, A D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Enoxaparin; Heparin; Lichen planus

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; LICHEN PLANUS; MALE; PRIORITY JOURNAL; REMISSION; SKIN BIOPSY; TREATMENT OUTCOME;

ADULT; AGED; DRUG EVALUATION; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; LICHEN PLANUS; MALE; MIDDLE AGED;

EID: 0033373872     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.03202.x     Document Type: Article

References (14)

1. 1 Porter SR, Kirby A, Olsen I, Barrett W. Immunologic aspects of dermal and oral lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83: 358-66.
2. 2 Tosca A, Varelzidis A, Michalopoulos M et al. In situ identification of mononuclear cells in lichen planus. Dermatologica 1983; 167: 113-20.
3. 3 Ingber A, Trattner A, Cohen IR, Mekori YA. Low doses of low molecular weight heparin in vivo inhibit the elicitation of contact hypersensitivity. Acta Derm Venereol (Stockh) 1994; 74: 454-6.
4. 4 Pillai S, Gilliam L, Conrad HE, Holleran WM. Heparin and its non-anticoagulant analogues inhibit human keratinocyte growth without inducing differentiation. J Invest Dermatol 1994; 103: 647-50.
5. 5 Piepkorn M, Pittelkow MR, Cook PW. Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol 1998; 111: 715-21.
6. 6 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
7. 7 Hodak E, Yosipovitch G, David M et al. Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J Am Acad Dermatol 1998; 38: 564-8.
8. 8 Naparstek Y, Cohen IR, Fuks Z, Vlodavsky I. Activated T lymphocytes produce a matrix-degrading heparan sulfate endoglycosidase. Nature 1984; 310: 241-3.
9. 9 Sipka S, Szilagui T. Mechanisms responsible for increased vascular permeability, fibrin deposits and chemotaxis in delayed hypersensitivity reactions. Br J Dermatol 1977; 97: 469-70.
10. 10 Varelzidis A, Tosca A, Perissios A, Capetanakis J. Immunohistochemistry in lichen planus. Dermatologica 1979; 159: 137-44.
11. 11 Ioannides D, Bystryn JC. Immunofluorescence abnormalities in lichen planopilaris. Arch Dermatol 1992; 128: 214-16.
12. 12 Cahalon L, Lider O, Schor H et al. Heparin disaccharides inhibit tumor necrosis factor-α production by macrophages and arrest immune inflammation in rodents. Intern Immunol 1997; 9: 1517-22.
13. 13 Spandau U, Toksoy A, Goebeler M et al. MIG is a dominant lymphocyte-attractant chemokine in lichen planus lesions. J Invest Dermatol 1998; 111: 1003-9.
14. 14 Yamamoto T, Osaki T. Characteristic cytokines generated by keratinocytes and mononuclear infiltrates in oral lichen planus. J Invest Dermatol 1995; 104: 784-8.